Last reviewed · How we verify
NCT05379608
Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.
NA trial testing Intermittent hypoxic-hyperoxic training in COVID-19 in 43 participants. Completed in 30 April 2025.
31 December 2023
Quick facts
| Lead sponsor | I.M. Sechenov First Moscow State Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 43 |
| Start date | 10 December 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Intermittent hypoxic-hyperoxic training
- Intermittent hypoxic-hyperoxic training/control
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
- Hypertension — all drugs for Hypertension →
- Arrhythmia — all drugs for Arrhythmia →
Sponsor
I.M. Sechenov First Moscow State Medical University
Who can join
Adults 40 to 75, any sex, with COVID-19 or Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of this prospective, interventional, single-center, randomized study is to evaluate the efficacy and safety of intermittent hypoxic-hyperoxic training (IHHT) as a rehabilitation method in patients with cardiovascular pathology in the early period after coronavirus infection. The study will include 60 patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University. The patients will be divided into 2 groups (intervention and control groups). Intervention group will inhale hypoxic gas mixtures (10-12% O2) followed by exposure to a hyperoxic gas mixture with 30-35% O2 5 times a week for 3 weeks, while control group will undergo a simulated IHHT. All the patients will undergo identical laboratory and instrumental testing before IHHT, after the last IHHT procedure, in a month after the last IHHT procedure and in 6 months. Estimated result of the study is to confirm or refute the hypothesis of the study that a three-week course of IHHT in patients with cardiovascular pathology in the early period after coronavirus infection can improve exercise tolerance, as well as the quality of life and psychoemotional status, and affect the dynamics of laboratory and instrumental parameters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05379608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other I.M. Sechenov First Moscow State Medical University trials
Trials by the same sponsor.
- NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
- NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
- NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
- NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
- NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05379608 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05379608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing